A method of treatment of disorders of the central nervous system and device for its implementation

 

(57) Abstract:

The invention relates to medicine and can be used in the treatment of the effects of generic and other brain injury or spinal cord, with paresis and paralysis, stroke and various ischemic disorders of the nervous structures. To extend functionality in the treatment of disorders of the Central nervous system to influence tissues located deep neck, brain and spinal cord in the way of treatment the impact of exercise on the projection of the lesion by radiation of a wavelength of 0.8-1.3 μm, the power density of 0.5 to 6 mW/cm2. Thus modulate the sensor signals of the pulse and respiration signals and pulse frequency tremor with additional modulation frequency 22,51 kHz. In a device for the treatment of disorders of the Central nervous system is entered N of laser emitters, the pulse generator carrier frequency and switching adder. 2 S. and 4 C.p. f-crystals, 2 Il.

The invention relates to medicine, in particular to neuropathology, and can be used in the treatment of the effects of generic and other brain injury or spinal cord, with paresis and paralysis, stroke and various ischemic disorders punctiliously lesions of the nervous structures [1-4]. They are not always effective, especially with the development of paralysis, demyelinizing processes and disorders of musculoskeletal system. The use of electrical stimulation [4] various kinds, including through implanted in the area of pathology electrodes, the current methods are not consistent with the provision of energy responses of cells and therefore does not guarantee the predominance of gain reduction processes over destructive. In our research proved that only as the hronofizioterapiya provides guaranteed strengthening plastic processes. For this exposure should increase only during the period of increasing energy stimulated cells, which corresponds to the increased blood supply to tissue, the opening of the capillary above the active cell, increased transportation energy metabolites and oxygen diffusion. In automatic mode this is not possible the selection of any frequency effects, but only on the control signals from sensors of the pulse and respiration of the patient [5-18].

There is a method of treatment of disorders of the Central nervous system, is the impact on the lesion pulses, modulated the device, containing connected in series sensor pulse, the first amplifier-shaper, the first potentiometer, the average output of which is connected to the first output of the adder, and consistently connected to the pressure sensor, the second amplifier-shaper, a second potentiometer, the average output of which is connected to the second input of the adder, the pulse generator frequency tremor and amplifier [5].

With automatic synchronization gain physical therapy effects with phases of increased blood supply to tissues steadily stimulated reductive biosynthetic processes that proved the case in the treatment of venous ulcers, periodontal disease, gastric ulcers and 12 duodenal ulcer, recovery of conduction of the nerve fibers at the disease of Stargardt and other diseases [7-18].

A method and device for modulation infrared laser radiation has allowed stable normalize in place of a pathology not only the level but also the range of rhythms of blood flow and microcirculation. It is specified that for sustainable normalization of blood flow and microcirculation at the site of pathology is necessary simultaneous laser action in an area of not less than 20-30 cm2.

However, a disadvantage of the known method and device using a laser irradiation on the brain and cervical spinal cord are limited functionality due to insufficient power density and other parameters of laser irradiation on the tissues located deep these bodies. The results of our research in the treatment of other diseases proved that for a sustainable normalization of blood flow and microcirculation at the site of pathology globalresortagency tissues of the internal organs of influence through biologically active points and zones Zakharyin-Ged using the known method and device is not effective.

The technical nature of nabliudeniam because of pericoloso lesions of the Central nervous system, at which carry out the effect of low-intensity laser radiation with a wavelength of 0.89+0.02 mm, the pulse frequency of 3000 Hz, the power pulse 0.7 W, contact for cervical segmental zones for a period of 32 (16 on each side of the spine), step by step from the 2nd to 7th paravertebral segments by two days for every two segments, daily for 10 days (see U.S. Pat. RF N2111026, class A 61 N 5/06 from 09.08.1994,)

However, this solution has limited functionality due to insufficient power density and other parameters of laser irradiation on the tissues located deep in the site of pathology.

The technical result is to increase functionality in the treatment of disorders of the Central nervous system to influence tissues located deep neck, brain and spinal cord.

This is achieved by the fact that in the method of treatment of disorders of the Central nervous system by the action of pulsed laser radiation according to the invention provide the effect in the projection of the lesion by radiation with a wavelength of 0.8 - 1.3 μm, the power density of 0.5 to 6 mW/cm2modulated sensor signals of the pulse and the breath is istia conducted over 300 30 shock the patient's heart rate every day for 10 - 15 days, at the stage of inflammation, and edema of the session is carried out in the first half of the day, during stimulation of biosynthetic recovery processes and enhance the regeneration of nerve fibers in the second half of the day in the evening, and device for treating disorders of the Central nervous system, containing connected in series sensor pulse, the first amplifier-shaper, the first potentiometer, the average output of which is connected to the first input of the adder, and connected in series the breath sensor, the second amplifier-shaper, a second potentiometer, the average output of which is connected to the second input of the adder, the pulse generator and the power amplifier, according to the invention is entered N of laser emitters, where N is an integer, the pulse generator carrier frequency and switching adder, and the output of the adder through a power amplifier connected to the first input dial adder, the second and the third inputs of which are connected the outputs of the pulse generator and the pulse generator carrier frequency, respectively, the input of each laser emitter connected to the output of dial-up adder, and outputs the laser emitters are located in the head Il is ewusie parameters:

pulsed power 30-200 watts;

wavelength in the range of 0.8-1.3 µm,

moreover, the switching adder can be made in the form of series-connected accumulator and the switch inputs of the adder are the first and second inputs of a dial adder, a third input which is combined with the control input of the switch, the output of which is the output of the signal adder.

The invention consists in that the use of laser emitters with corresponding parameters of the pulse generator carrier frequency and dial-up adder connected properly, allowed to provide the desired effect on tissues located deep neck, brain and spinal cord over a large area for sustainable normalization of blood flow and microcirculation.

Comparison of the proposed method and device with the closest analogues to judge according to the criterion of "novelty", and the lack of known analogues of the distinctive features of the claimed method and device says about the criterion of "inventive step".

Preliminary experimental and clinical studies to judge vozmozhnostnogo device, implements the proposed method of treatment.

In Fig. 2 is a timing diagram of operation of the device.

The device has connected in series sensor 1 pulse, the first amplifier-shaper 2, the first potentiometer 3 and connected in series respiration sensor 4, the second amplifier - shaper 5, a second potentiometer 6.

The average findings of the first and second potentiometers 3 and 6 are connected to first and second inputs of the adder 7, the output of which through the amplifier 8 is connected to the first input dial adder 9, the second and the third inputs of which are connected the outputs of the pulse generator 10 frequency tremor and generator 11 pulses of the carrier frequency of 22.5 1 kHz.

Exit dial-up adder 9 is connected to the inputs of the laser emitters 12-1 to 12-N (where N is an integer).

Switching adder 9 may be made in the form of serially connected adder 13 and the switch 16. The inputs of the adder 13 are first and second inputs of a dial adder 9, the third input is combined with the control input of the switch 14, the output of which is output dial adder 9.

The output of each laser emitter has the 10-50 cm2;

the average power density of 0.5 to 6 mW/cm2;

pulsed power 30-200 watts;

wavelength in the range of 0.8-1.3 μm.

As the laser oscillator, you can take the laser emitter output of the laser matrix, used in the known device, ALTO therapist-bio" (see L. 19), with the following parameters: a wavelength of 0.98 μm, the pulse power of 100 W, average power density of 0.5 to 6 mW/cm2the exposed area 30 cm2.

The operation of the device

The output of the laser matrix laser emitters 12-1 to 12-N have projected hearth disease of the brain or around the neck in the pathology of a cervical Department of a spinal cord. The number of laser emitters 12-i can be different and is determined by the depth and area of location of lesion pathology.

The generator 10 pulse frequency tremor is configured for a frequency of 8 Hz.

Typically, the frequency generator 10 is set arbitrarily to the session to avoid habituation effect.

Next, using the potentiometers 3 and 6 set the threshold, and the settings of the pulse.

The first amplifier-shaper 2 performs conversion that each negative pulse corresponds to one heart to reduce patient.

The second amplifier-shaper 5 converts the electric signal from the sensor 4 respiration in the voltage pulses shown in Fig. 3.

When the breath is an increase in the voltage at the output of the amplifier-shaper 5, when the exhalation is reduced.

The voltage outputs of the first and second amplifiers-formers 2 and 5 through the first and second potentiometers 3 and 6 are fed to the inputs of the adder 7, and its output through the amplifier 8 power at the first input dial adder 9. On the second and third inputs of the latter receives the pulses from the generators 10 and 11 of the pulse frequency of the tremor and the carrier frequency.

The pulses from the output of the amplifier 8 power generator 10 pulses the frequency of tremor are summed at the adder 13 and with its output through the switch 14 controlled from the pulse generator 11, the carrier frequency is converted into pulses with a frequency 22,51 kHz arrive at the laser emitters 12-1 to 12-n

Sessions of laser treatment should be performed within 10 to 15 days.

At the stage of inflammation, and edema session lasting about 5 minutes (biotyper 300 shock the patient's heart rate) is carried out in the first half of the day, when higher sympathetic tone.

On stage STI the second half of the day in the evening, when higher parasympathetic tone and navigates to the oxidation of fatty acids in oconostota futile cycle of energy.

The course duration is from 10 to 15 daily procedures individually controlled clinical results.

If necessary, nerve regeneration and the restoration coordination repeat courses of laser chronotherapy mode biofeedback with an interval of 1 month. This treatment does not exclude complex traditional treatment using medicines for individual readings. Other types of physical therapy are not used.

Studies have shown that, compared with existing methods of treatment of the proposed method and the device can provide effective treatment to patients for whom conventional therapies have been ineffective.

Examples of specific use of the present device and method (extracts from histories)

Example No. 1.

Patient P. , 2.5 years. Diagnosis: cerebral palsy. Deep psychomotor development. Spastic tetraplegia.

The patient was treated according to the above method of phenomena, hypersalivation, the child started to sit.

After the second course in a month spasticity virtually disappeared, appeared arbitrary motion of the upper extremities, the child confidently sit without support, appeared the skills articulate speech.

Example No. 2.

Patient S. , 64 years. In 1993 he suffered a stroke. Complaints of numbness in the left half of the body. The diagnosis of Atherosclerosis, cerebrovascular disease, Arterial hypertension. Left-side hemiparesis.

The patient was conducted 4 therapy on the above methodology for 2.5 months with 10-day intervals.

As a result of the treatment the patient's condition improved significantly, have confidence when walking (normalization motor stereotype), improved coordination of movement, appeared friendly movement of the hands and feet. Stabilized blood pressure, has a complicated movement in his left hand.

Thus, the proposed method and the device allow you to extend the functionality in the treatment of disorders of the Central nervous system to influence tissues located deep neck with.

2. Karpov Century A. Treatment of nervous diseases. M.: Medicine, 1987, 512 S.

3. Special physiotherapy. Sofia: Medicine and physical education, 1972, 522 S.

4. Yasnohorodska Century, Electrotherapy. M.: Medicine, 1987, 240 S.

5. Zaguskin S. L. Device for physiotherapy. RF patent N 2033204. Priority 4.09.89.

6. Zaguskin S. L., Zubko, Y. N. Device for electrotherapy. RF patent N 2067461. Priority 4.12.92.

7. Zaguskin S. L. Biorhythms: power and control. /Preprint IOFAN 236 N, M, 1986, 56 S.

8. Komarov F. I., Zagoskin S. L., Rapoport S. I. Chronobiological approach in medicine: as the hronofizioterapiya//Therapist. archive # 8 - 1994 - C. 3-6.

9. Zueva M. C., Tsapenko I. C., Dnistrova, I., Zagoskin S. L. Electroretinographic evaluation of the effectiveness of electrical stimulation of the retina by the method as hronofizioterapii when illness, Stargardt. //The. kurortol., 1994, No. 5. - S. 13-15.

10. Slyusarev S. L., and Rusakov, C. I., Bubnov Century. And., Zagoskin With HP As the hronofizioterapiya trophic ulcers of the lower extremities on the background of chronic venous insufficiency. //Clinical medicine, 1996, No. 6, S. 55-57.

11. Baryshevsky T. I. , Nancy T. B. Vasilieva E. E., Zagoskin S. L. Pulse infrakrasnogo Century. And., Zaguskin S. L., Bubnov Century. And., Sangeev A. C., Slyusarev S. L. , Chernogubov E. A. Method of treating inflammatory diseases of the male genital and lower urinary tract. //Application N 95103024. Priority 03.03.95, I promise. solved. 27.07.98,

13. Zaguskin S. L., Oraevsky C. N., Rapoport S. I., Grigoriev, A. I., the Method of controlling the pressure in the cuff sections of pneumomassage.//RF patent N 2103974, priority 27.09.96.

14. Rapoport S. I., Rasulov, M. I., Zagoskin S. L., Malinovskaya N. K. Sets Century. And. Method of treatment of gastric ulcer and 12 duodenal ulcer. Speaker of the USSR from 17.05.91. N 1736512. Priority 22.06.90.

15. Rusakov Century. And. , Zagoskin S. L., Slyusarev S. L., Bubnov Century. And. Method of treatment of venous ulcers. AC USSR N 1750702 from 28.03.91, priority 15.01.90.

16. Zaguskin S. L. Chronobiological direction of laser medicine. //New directions in laser medicine. Int. proc. M., 1996. - S. 296-297.

17. Zaguskin S. L. Apparatus and methods frontierlike and as hronofizioterapii. //Palliative medicine and rehabilitation, 1998, No. 4-5. - S. 12-13.

18. Zaguskin S. L. is it Possible to forecast and the guarantee of a positive effect of laser therapy? //The scientifically conference. scientific and practical use. proc. quantum therapy. A collection of articles. - M., 1998. - S. 30-32.

19. Instruction and technical the RT to the machine "Harmony". - NGO "country", Kazan, 1998.

1. A method of treatment of disorders of the Central nervous system by the action of pulsed laser radiation, characterized in that exercise influence in the projection of the lesion by radiation with a wavelength of 0.8-1.3 μm, the power density of 0.5 to 6 mW/cm2with the modulation signals of the sensors of the pulse and respiration and pulse signals of the frequency of tremor with additional modulation frequency 22,51 kHz.

2. The method according to p. 1, characterized in that the sessions of laser irradiation can be performed during 30030 shock the patient's heart rate daily for 10-15 days.

3. The method according to p. 1 or 2, characterized in that at the stage of inflammation, and edema of the session is carried out in the first half of the day, during stimulation of biosynthetic recovery processes and enhance the regeneration of nerve fibers in the second half of the day in the evening.

4. Device for the treatment of disorders of the Central nervous system, containing connected in series sensor pulse, the first amplifier-shaper, the first potentiometer, the average output of which is connected to the first input of the adder, and connected in series the breath sensor, the second amplifier-shaper, the second paragraph is nosti, wherein said introduced N laser emitters, where N is an integer, the pulse generator carrier frequency and switching adder, and the output of the adder through a power amplifier connected to the first input dial adder, the second and the third inputs of which are connected the outputs of the pulse generator and the pulse generator carrier frequency, respectively, the input of each laser emitter connected to the output of dial-up adder, and outputs the laser emitters are located in the head or spine of the patient in the projection of the lesion pathology.

5. The device according to p. 4, wherein each laser emitter output has the following parameters: peak power 30-200 W; wavelength of 0.8-1.3 μm.

6. The device according to p. 4, characterized in that the switching adder is made in the form of series-connected accumulator and the switch and the inputs of the adder are the first and second inputs of a dial adder, a third input which is combined with the control input of the switch whose output is the output of dial-up adder.

 

Same patents:
The invention relates to medicine and is intended for treatment of erysipelas
The invention relates to medicine, namely to otolaryngology

The invention relates to medicine and can be used for effective treatment of external and middle ear infections
The invention relates to medicine, endocrinology
The invention relates to medicine, ophthalmology

The invention relates to medicine, more specifically to a plastic ophthalmic surgery, in particular for blepharoplasty, and is intended for surgical removal of excess skin of the lower eyelid fat herniation or without them, with the weakening of tissue turgor lower eyelids

The invention relates to medicine, in particular to the pathology of the veins

The invention relates to medicine, and is intended for normalization of the functional status of platelets in infectious pathology

The invention relates to medical equipment and can be used in the apparatus for non-invasive therapeutic effects of laser radiation on the pathologic lesion

The invention relates to medicine, in particular to the treatment of ischemic heart disease

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vascular cutaneous neoplasms, such as nevus flammeus and gemangiomas. Light-thermal impact at energy ranged 39-47 J/sq. cm should be performed in two stages, and between them, 2-3 wk after the onset of vascular resistance at the first stage one should perform beta-therapy daily for 2-3 d at single dosage being 20 g. Then, 3 wk later it is necessary to conduct the second stage of light-thermal impact by starting at energy value being 42 J/sq. cm, not less. The method enables to shorten therapy terms due to applying combined method to affect vascular cutaneous neoplasms.

EFFECT: higher therapeutic and cosmetic effect.

1 ex

FIELD: medicine.

SUBSTANCE: method involves intravitreously introducing two electrodes into intraocular neoplasm after carrying out vitrectomy and retinotomy to expose the intraocular neoplasm. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with current intensity of 100 mA during 1-10 min or 10 mA during 10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2.The transformed retina and tumor destruction products are intravitreally removed. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. Another embodiment of the invention involves adjusting position and size of the intraocular neoplasm in trans-scleral diaphanoscopic way. Rectangular scleral pocket is built above the intraocular neoplasm to 2/3 of sclera thickness with its base turned away from limb. Several electrodes are introduced into intraocular neoplasm structure via the built bed. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with the same current intensity in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. Superficial scleral flat is returned to its place and fixed with interrupted sutures. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg after having carried out vitrectomy and retinotomy. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2. The transformed retina and tumor destruction products are intravitreally removed using vitreotome. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. The number of electrodes is equal to 4-8.

EFFECT: reduced risk of metastasizing.

4 cl, 13 dwg

FIELD: medicine.

SUBSTANCE: method involves building tunnel to posterior eyeball pole in inferoexterior and superexterior quadrants. The tunnel is used for implanting flexible polymer magnetolaser implant to the place, the subretinal neovascular membrane is localized. The implant has a permanent magnet shaped as a cut ring and is provided with drug delivery system and a short focus scattering lens of laser radiator connected to light guide. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 5-7 mTesla units intensity. It is arranged with its north pole turned towards sclera at the place of the subretinal neovascular membrane projection with extrascleral arrangement of laser radiator lens membrane being provided in the subretinal neovascular membrane projection area. The other implant end is sutured to sclera 5-6 mm far from the limb via holes made in advance. The implant is covered with conjunctiva and retention sutures are placed thereon. Light guide and drug supply system lead is attached to temple with any known method applied. Drugs are supplied via the implant drug supply system in retrobulbary way in any order. Triombrast is given in the amount of 0,4-0,6 ml and dexamethasone or dexone in the amount of 0,4-0,6 ml during 3-4 days every 12 h. 0.1-1% aqueous solution of khlorin is intravenously introduced at the third-fourth day after setting the implant as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, at a bolus dose of 0.8-1.1 mg/kg. Visual control of subretinal neovascular membrane cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the subretinal neovascular membrane with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at general dose of 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the subretinal neovascular membrane via laser light guide and implant lens, repeated laser irradiation of the subretinal neovascular membrane is carried out with radiation dose of 30-60 J/cm2.

EFFECT: accelerated subretinal edema and hemorrhages resorption; regression and obliteration of the subretinal neovascular membrane; prolonged vision function stabilization.

6 cl

FIELD: medicine.

SUBSTANCE: method involves filling vitreous cavity with perfluororganic compound. Two electrodes manufactured from platinum group metal are intravitreally, transretinally introduced into intraocular neoplasm. Electrochemical destruction is carried out with current intensity of 10-100 mA during 1-10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2 in perfluororganic compound medium. The transformed retina and tumor destruction products are intravitreally removed with perfluororganic compound volume being compensated with its additional introduction. Boundary-making endolasercoagulation of retinotomy area is carried out. The perfluororganic compound is substituted with silicon oil. The operation is ended in placing sutures over sclerotmy areas and over conjunctiva. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity. Platinum, iridium or rhodium are used as the platinum group metals.

EFFECT: complete destruction of neoplasm; reduced dissemination risk.

6 cl, 12 dwg

FIELD: medicine, applicable for stopping of pains of various nature.

SUBSTANCE: the device has a quantum-mechanical oscillator located in a casing, magnet, vessel for medicinal agent and a hollow cylinder. The magnet is installed between the oscillator and the vessel. Positioned in the vessel is a hollow cylinder having through holes on its surface.

EFFECT: quick and absolute anestesia.

2 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: method involves administering laser radiation therapy once a day using low intensity pulsating radiation of wavelength equal to 890nmand power density of 0.03 mW/cm2. Injured organ projection to frontal abdominal wall is exposed to radiation at the first laser therapy stage in two fields acting upon each field for 2 min with radiation pulse succession frequency equal to 80 Hz in applying stable contact-type method. Total treatment dose on two fields is equal to 0.008 J/cm2. The second laser therapy stage begins immediately after having finished the first one in applying radiation along the large intestine path using labile contact-type method in a way that radiation pulse succession frequency equal to 80 Hz is applied first during 1 min and then frequencies of 600, 150 and 300 Hz are applied also during 1 min, respectively. Total treatment dose is equal to 0.032 J/cm2 at the second stage. Total treatment dose is equal to 0.04 J/cm2 at both stages.

EFFECT: enhanced effectiveness in inhibiting dysbacteriosis; reduced frequency of postoperative complications.

Up!